Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
April 14, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Names David M. Denton Chief Financial Officer
April 11, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
April 07, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
March 29, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
March 29, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
March 24, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
March 23, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
March 22, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries
March 22, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference
February 22, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
February 15, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
OPK
PFE
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
February 15, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
February 11, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 09, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
February 08, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
February 01, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces New Chief Development Officer
February 01, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
January 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
January 27, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
January 21, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
OPK
PFE
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
January 14, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
January 12, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BEAM
PFE
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
January 05, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
January 03, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.